NBT Bank N A NY Cuts Stake in Celgene Corporation (CELG)

NBT Bank N A NY lessened its holdings in Celgene Corporation (NASDAQ:CELG) by 10.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,094 shares of the biopharmaceutical company’s stock after selling 2,125 shares during the quarter. NBT Bank N A NY’s holdings in Celgene Corporation were worth $2,350,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in CELG. Neuberger Berman Group LLC grew its position in shares of Celgene Corporation by 4.0% during the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock worth $229,553,000 after buying an additional 71,729 shares during the period. Grisanti Capital Management LLC acquired a new stake in shares of Celgene Corporation during the 2nd quarter worth approximately $3,616,000. Lincoln Capital Corp grew its position in Celgene Corporation by 0.6% in the 2nd quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after purchasing an additional 185 shares during the period. Swiss National Bank grew its position in Celgene Corporation by 27.2% in the 1st quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after purchasing an additional 588,000 shares during the period. Finally, RiverPoint Capital Management LLC grew its position in Celgene Corporation by 3.1% in the 2nd quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after purchasing an additional 3,680 shares during the period. Hedge funds and other institutional investors own 79.16% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2017/11/13/nbt-bank-n-a-ny-decreases-holdings-in-celgene-corporation-celg.html.

Celgene Corporation (NASDAQ CELG) opened at $102.34 on Monday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The stock has a market capitalization of $80,574.02, a P/E ratio of 15.99, a P/E/G ratio of 0.79 and a beta of 1.79. Celgene Corporation has a 12-month low of $94.55 and a 12-month high of $147.17.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. Celgene Corporation’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm posted $1.58 EPS. analysts predict that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.

In other Celgene Corporation news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the transaction, the director now directly owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 20,227 shares of company stock valued at $2,843,956. Insiders own 0.95% of the company’s stock.

A number of equities analysts have issued reports on CELG shares. Morgan Stanley downgraded shares of Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective on the stock. in a report on Thursday, October 5th. BTIG Research reiterated a “hold” rating on shares of Celgene Corporation in a research note on Sunday, October 22nd. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $144.39 price target on the stock in a research report on Monday, October 23rd. Citigroup Inc. lowered Celgene Corporation from a “buy” rating to a “neutral” rating in a report on Friday, October 20th. Finally, Guggenheim assumed coverage on Celgene Corporation in a report on Monday, October 23rd. They set a “buy” rating and a $160.00 price objective for the company. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $139.64.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply